Bollard Group’s CorMedix CRMD Stock Holding History

Bollard Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-80,384	Closed	-$209K	–	256
2017 Q3	$209K	Hold	80,384	–	–	0.01%	174
2017 Q2	$172K	Hold	80,384	–	–	0.01%	188
2017 Q1	$655K	Hold	80,384	–	–	0.04%	149
2016 Q4	$615K	Hold	80,384	–	–	0.04%	152
2016 Q3	$1.01M	Sell	80,384 -21,831	-21%	-$204K	0.06%	134
2016 Q2	$1.02M	Hold	102,215	–	–	0.07%	133
2016 Q1	$1.35M	Hold	102,215	–	–	0.11%	106
2015 Q4	$1.04M	Hold	102,215	–	–	0.09%	125
2015 Q3	$1.02M	Hold	102,215	–	–	0.08%	134
2015 Q2	$1.98M	Hold	102,215	–	–	0.15%	96
2015 Q1	$5.03M	Buy	+102,215	New	+$2.42M	0.37%	47

Other funds holding CRMD

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Bollard Group's CRMD Position: Q4 2017 in Review

Bollard Group sold out of CorMedix (CRMD) in Q4 2017, closing a stake of 80,384 shares — an estimated $209K sold.

Bollard Group first reported a position in CRMD in Q1 2015 and held it in 11 quarters. The position peaked at $5.03M in Q1 2015. 34 funds tracked by Wall St. Rank hold CRMD as of Q4 2017.

Bollard Group reported no remaining CorMedix position as of Q4 2017 after selling out during the quarter.
Bollard Group sold 80,384 CorMedix shares in Q4 2017, an estimated $209K.
Bollard Group first reported a position in CorMedix in Q1 2015 and held it in 11 quarters.
Bollard Group's CorMedix position peaked at $5.03M in Q1 2015.
34 funds tracked by Wall St. Rank held CorMedix as of Q4 2017.

Based on Bollard Group's 13F filing for Q4 2017, filed 29 Jan 2018.